Bookmark Current Page
Edit Metric
|
||||||||||||||||||||
Details
|
||||||||||||||
| 
Edit
History
Bulls: Reasons To Buy
Feeling Bullish?
Be the first to explain why this would make a good investment
Bears: Reasons To Sell
Feeling Bearish?
Be the first to explain why this would make a poor investment
|
Top Contributors
|
ev3 (EVVV), headquartered in Plymouth Minnesota, went public on June 21, 2005. The company concentrates on catheter-based, or endovascular, technologies for the minimally invasive treatment of vascular diseases and disorders. The company's acquired broad product portfolio is focused, hence its corporate name, on applications in each of the three sub-markets of the endovascular device market: peripheral vascular, cardiovascular and neurovascular. The company develops, manufactures, and markets an extensive variety of products like stents, embolic protection devices, thrombectomy devices, balloon angioplasty catheters, retrieval devices, guidewires, embolic coils, liquid embolics, microcatheters, and occlusion balloon systems. The company operates in principally two product segments: cardio peripheral and neurovascular. The cardio peripheral segment consists of products that are used by cardiologists, radiologists, vascular surgeons, and other specialists in both cardiovascular and peripheral vascular procedures. The products in the segment include stents, thrombectomy devices, and embolic protection devices, and procedural support devices and others. The neurovascular division, principally Micro Therapeutics, includes products that are used primarily by neuro-radiologists and neurosurgeons for neurovascular procedures. This segment comprises embolic products, and neuro access and delivery products. The company completed the acquisition of all of the outstanding shares of Micro Therapeutics that it did not already own on January 6, 2006. In October 2007, ev3 Inc. and FoxHollow Technologies, Inc. completed their merger whereby EVVV acquired all the outstanding shares of FoxHollow common stock, resulting in FoxHollow becoming a wholly owned subsidiary of ev3.
The company's combined product portfolio will include a broad array of products to treat vascular disease in both the peripheral and neurovascular markets, including atherectomy and thrombectomy, PTA balloons, stents, embolic protection devices, infusion catheters/wires, embolic coils and liquid embolics.
The combined company's ownership composition consisted of approximately 41% from FoxHollow stockholders and 59% from ev3 stockholders.
The company sells over 100 products in more than 50 countries. Operating a direct sales force in the United States, Europe, Canada, and Japan, ev3 markets through distributors in other international markets. For 2007, U.S. revenues represented 62% of total revenues, with international revenues contributing 38%.
